zurig是什么药？

What kind of medicine is it? Zurig (febuxostat) is a new non-purine xanthine oxidase (XO) selective inhibitor. It was approved for marketing by European EMEA in April 2008 and by the US FDA in February 2009. It is the first new anti-gout drug approved by the FDA in the past 40 years.

Compared with similar drugs, zurig (febuxostat) has high selectivity and stronger activity. Its efficacy is better than that of allopurinol, the current gold standard treatment for gout, and it has rapid efficacy and mild adverse reactions. As a new anti-uric acid drug, zurig (febuxostat) has ended the history of allopurinol being the only drug in the world, created a new era of gout treatment, and provided new treatment options for gout patients.

The starting dose of zurig is 40 mg once daily. If the blood uric acid level is still not less than 6 mg/dl (approximately 360 μmol/L) after 2 weeks, it is recommended that the dose be increased to 80 mg once a day. Food and antacid effects do not need to be considered when administering the drug. Patients with mild or moderate hepatic insufficiency (Child-Pugh Class A, B) do not need to adjust the dose, and patients with severe hepatic insufficiency (Child-Pugh Class C) should use zurig with caution.

Notes on zurig:

1. Gout attack: In the early stage of taking zurig, gout attack may occur. This is caused by changes in uric acid levels so that urate deposited in tissues is mobilized. In this case, there is no need to stop taking the drug. Taking non-steroidal anti-inflammatory drugs or colchicine at the same time during the initial use of zurig can prevent gout attacks.

2. Cardiovascular events: So far, the causal relationship between this drug and cardiovascular thrombotic events has not been determined, but the zurig80mg group had more cardiovascular events, so symptoms and signs of myocardial infarction and cardiovascular death should be monitored when taking the drug.

3. Secondary hyperuricemia: This drug has not been studied in patients with secondary hyperuricemia, so its use is not recommended for patients with secondary hyperuricemia.

4. Effects on the liver: Patients who use zurig will experience abnormal liver function, such as fatigue, loss of appetite, jaundice, diarrhea, headache, etc. During clinical medication, when abnormal liver function is found in patients, the medication should be discontinued and the possible cause should be determined as much as possible. If the cause is unclear, it is not suitable to be used on these patients.